Wall Street analyst estimates for Invivyd, Inc. (IVVD): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.11 | ||
| 2026-08-13 | $-0.14 | $-0.11 | -31.2% |
| 2026-05-14 | $-0.13 | $-0.08 | -62.5% |
| 2026-03-05 | $0.02 | $-0.06 | +133.3% |
| 2025-11-06 | $-0.06 | $-0.05 | -20.0% |
| 2025-08-14 | $-0.12 | $-0.04 | -200.0% |
| 2025-05-15 | $-0.14 | $-0.04 | -250.0% |
| 2025-03-20 | $-0.15 | $-0.25 | +40.0% |
Valuation Ratios
| Price / Book | 1.44 |
| EV / EBITDA | -0.85 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | $25.4M | $53.4M |
| Cost of Revenue | 0 | 0 | 0 | 0 | $1.6M | $3.7M |
| Gross Profit | 0 | 0 | 0 | 0 | $23.8M | $49.7M |
| Research & Development | $106.5M | $182.9M | $179.2M | $158.7M | $137.3M | $38.3M |
| Selling, General & Admin | $5.5M | $36.5M | $47.0M | $49.1M | $63.4M | $66.9M |
| Operating Expenses | $112.0M | $226.9M | $248.0M | $212.8M | $200.6M | $105.2M |
| Operating Income | -$112.0M | -$226.9M | -$248.0M | -$212.8M | -$176.9M | -$55.6M |
| EBITDA | 0 | -$219.4M | -$225.8M | -$205.8M | -$166.8M | -$50.4M |
| Interest Expense | 0 | 0 | $43.1M | 0 | 0 | 0 |
| Pre-tax Income | -$112.0M | -$226.8M | -$241.3M | -$198.6M | -$169.9M | -$52.5M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$112.0M | -$226.8M | -$241.3M | -$198.6M | -$169.9M | -$52.5M |
| EPS | $-0.59 | $-2.11 | $-2.17 | $-1.81 | $-1.43 | $-0.30 |
| EPS (Diluted) | $-0.59 | $-2.11 | $-2.17 | $-1.81 | $-1.43 | $-0.30 |
| Shares Outstanding (Diluted) | $111.2M | $110.8M | $108.3M | $109.5M | $118.6M | $172.2M |
Price
| Price | $0.81 |
| Market Cap | $237M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CCCC · CDXS · GNFT · IMDX · NTHI · OABI · OBIO
Explore sector: Healthcare · Biotechnology
More sections of IVVD: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks